Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
26. November 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
13. November 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
07. November 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
28. Oktober 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
23. Oktober 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
28. August 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
19. August 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
08. August 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
08. Juli 2024 08:36 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
27. Juni 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160